CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, today announced that clinical results from its Phase 1 MYE Symphony trial ...

Biogen Inc. ? will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology's (ASN) annual meeting, taking place November 5-9 in ...

Snow White will be full of live folksy music and fun, some lovely songs and a comic collection of forest-dwelling misfits." ...

Called Neffy, it offers a needle-free alternative to the EpiPen used by those at risk of potentially fatal anaphylaxis to inject themselves with adrenaline.

The early-stage pipeline for amyotrophic lateral sclerosis drugs exploded last year. After ALS R&D notched 28 new trial starts in 2023, the rate more than doubled to 60 in 2024, Citeline recently ...

The fate of Cursor and Replit and the rest could follow a number of paths. Cursor recently announced it is developing its own ...

Alnylam Pharmaceuticals Inc. ALNY) on Thursday reported third-quarter net income of $251.1 million, after reporting a loss in the same period a year earlier.

Attima Hadlari, a longtime board member of Nunavut Tunngavik Inc. (NTI), drum dancer and founding president of Red Fish Arts ...

Waterloo Region staff recommend LRT extension from Fairway Station to Ainslie Street in Cambridge, aiming for federal and ...

The Business Courier will reveal the Power 25: Growth Champions in the print edition Nov. 14. The Business Courier will ...

A year after Boston's inclusionary zoning policy was made more aggressive, developers and politicians have criticized it for ...

Biogen Inc. and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen's immunology ...